Nina Kadan-Lottick, MD
Associate Professor of Pediatrics (Hematology / Oncology) and Medical Director, HEROS Program
Specialty
Pediatrics: Pediatric Hematology & Oncology
Programs & Centers
Pediatric Hematology & Oncology Program, Cancer Center, Yale, Supportive Oncology Program, Pediatric Specialty Center, Hematology Program, Yale Adult Survivorship Clinic
Clinical Interests
Late effects of cancer therapy, including osteoporosis, growth failure, neurocognitive deficits, infertility, cardiomyopathy, and second neoplasms; Childhood cancer survivorship; Treatment of acute childhood leukemia and other childhood malignancies; Diagnosis and treatment of hypoglobinopathies; Quality of life of childhood cancer patients; Sarcomas; lymphoma; Brain tumors; Blood disorders; Thrombocytopenia; Hematologic disorders; Immune hematologic disorders
|
Cancers Treated:
Pediatric,
Supportive Care Accepts New Patients? Yes Patient Type: Child Accepts appointments from patients or physicians |
Board Certifications
- Hematology-Oncology, Board Certified 2000, Recertified 2008
Education & Training
- Fellow, University of Minnesota, Minneapolis, MN, Cancer Epidemiology, 2000
- Fellow, The Children's Hospital, University of Colorado Health Sciences, Denver, CO, Pediatric Hematology/Oncology, 1999
- Resident, Johns Hopkins Hospital, Baltimore, MD, Pediatrics, 1996
- Intern , Johns Hopkins Hospital, Baltimore, MD, Pediatrics, 1994
- M.D., Johns Hopkins University School of Medicine, 1993
Clinical Research
|
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
Disease/Condition: Adult Rhabdomyosarcoma; Alveolar Childhood Rhabdomyosarcoma; Mixed Childhood Rhabdomyosarcoma; Pleomorphic Childhood Rhabdomyosarcoma; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Rhabdomyosarcoma |
|
Study of Blood Samples From Newborns With Down Syndrome
Disease/Condition: Down Syndrome; Leukemia |
|
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy
Disease/Condition: Fungal Infection; Leukemia; Neutropenia |
|
A Phase II Study of Cixutumumab (IMC-A12; IND# 100947) in Combination with Temsirolimus (IND# 61010) in Pediatric Patients with Recurrent or Refractory Solid Tumors (ADVL1221)
Disease/Condition: Recurrent or Refractory Solid Tumors |
Yale Pediatric Hematology/Oncology
South Frontage Road and Park Street, New Haven, CT 06510
|
Appts (203) 785-4640 |
Fax (203) 737-2228 |
Schedule an Appointment
Appointment Phone
(203) 785-4081
Appointment Fax
(203) 737-2228
Office Phone
(203) 785-4640
nina.kadan-lottick@yale.edu
Location
Yale Pediatric Hematology/Oncology
Smilow Cancer Hospital at Yale - New Haven
South Frontage Road and Park Street
7th Floor
New Haven, CT 06510
(203) 785-4640 - Appts.
(203) 737-2228 - Fax
